Computational approaches to study oncolytic virus therapy : insights and challenges

The paper reviews computational models for analyzing the use of replicating oncolytic viruses as therapeutic agents against cancers. The paper highlights viral and host paramters which are crucial for success, and discusses how virus strains can be optimized in order to achieve maximial remission of cancers. The models consider three mechansisms by which oncolytic virus therapy could work: (i) virus-mediated killing of tumor cells. (ii) Induction of immune responses against the virus which can kill infected tumor cells. (iii) Induction of tumor specific immune responses following the release of stimulatory signals as a result of the virus infection. The models further give rise to insights into how virus variants should be tested in vitro in order to determine their therapeutic potential.

[1]  D. Kirn,et al.  Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. , 1999, Cancer research.

[2]  P. Matzinger,et al.  Is cancer dangerous to the immune system? , 1996, Seminars in immunology.

[3]  W. Rom,et al.  Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved--deletion of the viral E1b-19-kD gene increases the viral oncolytic effect. , 2001, Human gene therapy.

[4]  R. Gatenby,et al.  Application of competition theory to tumour growth: implications for tumour biology and treatment. , 1996, European journal of cancer.

[5]  D. Kirn,et al.  Replicating viruses as selective cancer therapeutics. , 1996, Molecular medicine today.

[6]  Cheng-Ta Yang,et al.  ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients. , 2000, Cancer research.

[7]  Nicola Bellomo,et al.  A Survey of Models for Tumor-Immune System Dynamics , 1996 .

[8]  D. Kirschner,et al.  Modeling immunotherapy of the tumor – immune interaction , 1998, Journal of mathematical biology.

[9]  F. McCormick,et al.  ONYX-015: Clinical data are encouraging , 1998, Nature Medicine.

[10]  D. Kirn,et al.  ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents , 1997, Nature Medicine.

[11]  D. Kirn,et al.  Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: Intratumoral spread and distribution effects , 1999, Cancer Gene Therapy.

[12]  Anthony R. Hall,et al.  p53-dependent cell death/apoptosis is required for a productive adenovirus infection , 1998, Nature Medicine.

[13]  F. McCormick,et al.  New molecular targets for cancer therapy. , 1996, Scientific American.

[14]  I. Tannock,et al.  A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer , 2000, Nature Medicine.

[15]  Dominik Wodarz,et al.  Gene therapy for killing p53-negative cancer cells: use of replicating versus nonreplicating agents. , 2003, Human gene therapy.

[16]  D. Kirn,et al.  In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. , 2000, Cancer research.

[17]  D. Wodarz,et al.  Viruses as antitumor weapons: defining conditions for tumor remission. , 2001, Cancer research.

[18]  M. Gulley,et al.  A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  A. Braithwaite,et al.  Efficient Induction of Cell Death by Adenoviruses Requires Binding of E 1 B 55 k and p 531 , 2000 .

[20]  P. Matzinger,et al.  An innate sense of danger. , 1998, Seminars in immunology.

[21]  E. T. Gawlinski,et al.  A reaction-diffusion model of cancer invasion. , 1996, Cancer research.

[22]  J. H. Kim,et al.  A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. , 1998, Human gene therapy.